regardless of promising clinical results, copyright's Vyndamax, a therapy for hereditary transthyretin-mediated amyloidosis (hATTR), is encountering significant opposition from PBMs. The insurers are typically creating limitations to reimbursement, including high expense criteria and PA that hind